Utomilumab  (Synonyms: PF 05082566)

Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20⁺ non-Hodgkin lymphomas^[1][2][3].

Human IgG2 Lambda2

Utomilumab (1-10 mg/kg) is well tolerated in the PBMC humanized mouse model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

142.78 kDa

1417318-27-4

Liquid

Colorless to light yellow

[Utomilumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 lambda

• 
  Immobilized 4-1BB/TNFRSF9 Protein, Human can bind Utomilumab. The EC₅₀ for this effect is 6.92 ng/mL.

• [1]. Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357.  [Content Brief]

  [2]. Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20⁺ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534.  [Content Brief]

  [3]. Rose D, et al. 1258 PBMC humanized mouse model with clinical relevance in assessing the safety profile of 4–1BB agonists utomilumab and urelumab. 2022.